The New England Journal of Medicine Publishes Results of Final Landmark Phase III Efficacy Clinical Study of Sanofi Pasteur’s Dengue Vaccine Candidate

Study successfully met primary objective and confirms high efficacy against severe dengue and hospitalization Sanofi Pasteur intends to file for registration in several endemic countries in 2015 Dengue vaccine candidate would address an urgent unmet medical need in tropical and sub-tropical regions of the world November 3, 2014 Sanofi Pasteur, the vaccines division of Sanofi, today announced the publication of …

The World’s First, Large-Scale Dengue Vaccine Efficacy Study Successfully Achieved Its Primary Clinical Endpoint

First available data demonstrated a 56% reduction of dengue disease cases in a study of more than 10,000 volunteers from Asia Initial safety data are consistent with the good safety profile observed in previous studies April 28, 2014 Sanofi Pasteur, the vaccines division of Sanofi, today announced that the first of two pivotal Phase III efficacy studies with its dengue …